Most providers say the liver ruins oral E2.
How? Via the infamous first-pass effect.
What is the First-Pass Effect?
The first-pass effect (also called first-pass metabolism) occurs when oral medications are absorbed via the portal vein from the intestines and processed by the liver before they hit systemic circulation.
In medicine, this is often seen as a bug.
It’s annoying. It gets in the way. It reduces the “purity” of the drug.
But in the case of oral estradiol (E2)… this “bug” might be the feature that makes it work so well.
What Happens to Oral Estradiol?
When oral E2 is taken, it’s mostly converted to:
- Estrone (E1)
- Estrone sulfate (E1-S)
This conversion happens because of the liver’s enzymatic processes during first-pass metabolism.
This brings up two concerns in most provider discussions:
- Increased risk of blood clots
- Increased risk of cancer
Does Oral E2 Increase Clot Risk?
No.
The idea that oral estradiol increases clotting risk is outdated and not supported by current evidence.
Recent trials show that properly dosed PO E2 does not increase the risk of clots at all.
Zero. None.
If you want more details, reply to my newsletter and I’ll send you the full breakdown.
What About Cancer Risk from Estrone?
Here’s where it gets interesting.
Estrone is a weaker estrogen than E2, but it binds more readily to ER-alpha (ERα) receptors, which are associated with:
- Uterine and breast tissue proliferation
- Theoretical cancer risk
The fear is that this could lead to increased breast or uterine cancer risk.
But the truth?
Studies Show Oral E2 Is Safe
The REPLENISH Trial and many others show no increase in cancer risk with oral estradiol.
In fact, outcomes often improve, particularly when therapy is done correctly.
Why the First-Pass Effect Might Be a Good Thing
Let’s bring in an HRTU Principle here:
Hormone replacement therapy is not a 1:1 match with endogenous hormone production.
You cannot equate HRT metabolism to what happens naturally in the body.
Estrone and estrone sulfate serve a powerful role. They act as a reservoir, circulating with a long half-life.
When the body needs more estradiol, estrone sulfate converts back into E2.
This often explains why:
- Serum E2 may appear low on labs
- But clinical effects are stable and patients feel good
Conclusion: The First-Pass Effect Is Not a Problem
The first-pass effect is not a flaw of oral estradiol.
It may actually be the feature that gives it long-term, stable results in patients.
PO E2 does not increase clots or cancer when done right.If anything, it improves cardiovascular and all-cause mortality outcomes.
